| Literature DB >> 28529844 |
Pedro Santos Leite1, Sérgio Figueiredo1, Ricardo Sousa1.
Abstract
Background: Prosthetic Joint Infection (PJI) is one of the most challenging problems in orthopaedic surgery and musculoskeletal infections specifically. Some very important controversies remain and strong evidence-based recommendations are still lacking in many clinical aspects. Therefore, an undisputed methodology of treatment does not exist yet and there are many different valid approaches. Purposes: To draw a picture of the different practice patterns around Europe and understand the motivations of the European Bone & Joint Infection Society (EBJIS) members in choosing between one- or two-stage revision surgery in treating chronic PJI.Entities:
Keywords: One-stage Exchange; Prosthetic Joint Infection; Two-stage Exchange.
Year: 2016 PMID: 28529844 PMCID: PMC5423559 DOI: 10.7150/jbji.14671
Source DB: PubMed Journal: J Bone Jt Infect ISSN: 2206-3552
Figure 1Geographical distribution of respondents.
Personal and Institutional information.
| Orthopaedics | Infectious Diseases | Microbiology | Other | |
| 114 [81.4%] | 15 [10.7%] | 7 [5.0%] | 4 [2.9%] | |
| Head of Department | Consultant | Attending | Resident | |
| 28 [20.0%] | 64 [45.7%] | 16 [11.4%] | 32 [22.9%] | |
| 0-2 years | 3-5 years | 6-10 years | >10 years | |
| 20 [14.3%] | 40 [28.6%] | 24 [17.1%] | 50 [35.7%] | |
| University Hospital | Public Health System | Private Hospital | Other | |
| 75 [53.6%] | 51 [36.4%] | 12 [8.6%] | 2 [1.4%] | |
| < 200 | 200-500 | 500-1000 | >1000 | |
| 28 [20.4%] | 50 [36.5%] | 29 [21.2%] | 30 [21.9%] | |
| < 20 | 20-50 | 50-100 | > 100 | |
| 43 [31.2%] | 60 [43.5%] | 24 [17.4%] | 11 [7.9%] |
MSK - Musculoskeletal; TJA - Total Joint Arthroplasty; PJI - Prosthetic Joint Infection.
Bone & Joint Infection Unit.
| YES | NO | |||||
| 72 [51.8%] | 67 [48.2&] | |||||
| Orthopaedics | Infectious Diseases | Microbiology | Anaesthesiology | Internal Medicine | Plastic surgeon | Other |
| 128 [92.9%] | 93 [86.9%] | 104 [74.8%] | 59 [42.5%] | 51 [36.7%] | 59 [42.5%] | 17 [12.2%] |
B&J - Bone and Joint.
Philosophy regarding chronic PJI requiring revision surgery.
| Primarily Two-stage | Two-stage or One-stage accordingly | Primarily One-stage | |||
| 83 [60.1%] | 48 [34,8%] | 7 [5,1%] | |||
| Residual | <20% | 20-50% | 50-80% | >80% | |
| 52 [44.4%] | 33 [28.2%] | 22 [18.8%] | 5 [4.3%] | 5 [4.3%] | |
| Residual | <20% | 20-50% | 50-80% | >80% | |
| 46 [54.1%] | 20 [23.5%] | 0 [0.0%] | 0 [0.0%] | 1 [1.2%] | |
| Residual | <20% | 20-50% | 50-80% | >80% | |
| 7 [14.6%] | 13 [27.1%] | 21 [43.5%] | 4 [6.9%] | 0 [0.0%] | |
| Residual | <20% | 20-50% | 50-80% | >80% | |
| 0 [0.0%] | 1 [12.5%] | 1 [12.5%] | 1 [12.5%] | 4 [50.0%] | |
PJI - Prosthetic Joint Infection
Delegates voting on importance of several factors in their choice for Two-stage and NOT One-stage procedures
| 16 [11.5%] | 30 [21.6%] | 52 [37.4%] | 26 [1870%] | 15 [10.8%] | 3.0/5 | |
| 32 [22.9%] | 20 [14.3%] | 35 [25.0%] | 35 [25.0%] | 18 [12.9%] | 3.0/5 | |
| 26 [18.6%] | 16 [11.4%] | 29 [20.7%] | 37 [26.4%] | 32 [22.9%] | 3.2/5 | |
| 21 [15.2%] | 27 [19.6%] | 41 [29.8%] | 32 [23.2%] | 17 [12.3%] | 3.0/5 | |
| 14 [10.2%] | 20 [14.6%] | 41 [29.9%] | 49 [35.8%] | 13 [9.5%] | 3.2/5 | |
| 42 [30.7%] | 39 [28.5%] | 32 [23.4%] | 22 [16.1%] | 2 [1.5%] | 2.3/5 | |
| 5 [3.6%] | 19 [13.8%] | 27 [19.6%] | 48 [34.8%] | 39 [28.3%] | 3.7/5 | |
| 20 [14.6%] | 30 [21.9%] | 48 [35.0%] | 21 [15.3%] | 18 [13.1%] | 3.0/5 | |
| 8 [5.8%] | 16 [11.7%] | 36 [26.3%] | 45 [32.9%] | 32 [23.4%] | 3.6/5 |
PJI - Prosthetic Joint Infection
Delegates voting on importance of several factors in choosing Two-stage and NOT One-stage procedures.
| 9 [6.5%] | 11 [8.0%] | 27 [19.6%] | 37 [26.8%] | 54 [39.1%] | 3.8/5 | |
| 10 [7.3%] | 10 [7.3%] | 25 [18.3%] | 37 [27.0%] | 55 [40.2%] | 3.9/5 | |
| 16 [11.6%] | 25 [18.1%] | 32 [23.2%] | 39 [28.3%] | 26 [18.9%] | 3.3/5 | |
| 16 [11.6%] | 22 [15.9%] | 39 [28.3%] | 46 [33.3%] | 15 [10.9%] | 3.2/5 | |
| 16 [11.7%] | 28 [20.4%] | 42 [30.7%] | 27 [19.7%] | 24 [17.5%] | 3.1/5 | |
| 25 [18.4%] | 23 [16.9%] | 42 [30.9%] | 24 [17.7%] | 22 [16.2%] | 3.0/5 | |
| 6 [4.4%] | 9 [6.6%] | 30 [22.1%] | 43 [31.6%] | 48 [35.3%] | 3.9/5 | |
| 9[6.6%] | 15 [11.0%] | 32 [23.4%] | 45 [32.9%] | 36 [26.3%] | 3.6/5 | |
| 10 [7.4%] | 17 [12.5%] | 43 [31.6%] | 42 [30.9%] | 24 [17.7%] | 3.4/5 | |
| 23 [17.0%] | 52 [38.5%] | 41 [30.4%] | 16 [11.9%] | 3 [2.2%] | 2.4/5 | |
| 12 [8.8%] | 37 [27.2%] | 36 [26.5%] | 32 [23.5%] | 19 [14.0%] | 3.1/5 |
MRSA - Methicillin Resistant S.aureus; VRE - Vancomicyn Resistant Enterococci; ESBL- Extended Spectrum Beta Lactamase; MR - Methicillin Resistant.
Figure 2A. Importance of different factors according to the philosophy of revision. B. Importance of different factors according to the philosophy of revision.
Personal, Local and Institutional Factors influence on chosen philosophy for revision surgery
| Primarily Two-stage | Two-stage or One-stage accordingly | Primarily One-stage | P value | |
|---|---|---|---|---|
| Head of Department | 12 [44.4%] | 12 [44.4%] | 3 [11.1%] | 0.328 |
| Consultant | 38 [59.4%] | 23 [35.9%] | 3 [4.7%] | |
| Attending | 13 [81.2%] | 3 [18.8%] | 0 [0.0%] | |
| Resident | 21 [63.6%] | 10 [30.3%] | 2 [6.1%] | |
| >0-2 years | 12 [70.6%] | 5 [29.4%] | 0 [0.0%] | 0.604 |
| 2-5 years | 26 [65.0%] | 13 [32.5%] | 1 [2.5%] | |
| 6-10 years | 12 [50.0%] | 10 [41.7%] | 2 [8.3%] | |
| >10 years | 28 [56.0%] | 18 [36.0%] | 4 [8.0%] | |
| University Hospital | 48 [62.4%] | 26 [33.8%] | 3 [3.9%] | 0.309 |
| Public Health System | 28 [54.9%] | 20 [39.2%] | 3 [5.9%] | |
| Private Hospital | 9 [69.2%] | 2 [15.4%] | 2 [15.4%] | |
| < 200 | 21 [77.8%] | 6 [22.2%] | 0 [0.0%] | 0.020 |
| < 200-500 | 30 [57.7%] | 15 [28.8%] | 7 [13.5%] | |
| 500-1000 | 17 [46.7%] | 12 [40.0%] | 1 [3.3%] | |
| >1000 | 15 [50.0%] | 15 [50.0%] | 0 [0.0%] | |
| < 20 | 29 [69.0%] | 12 [28.6%] | 1 [2.4%] | 0.655 |
| 20-50 | 33 [53.2%] | 24 [38.7%] | 5 [8.1%] | |
| 50-100 | 17 [68.0%] | 7 [28.0%] | 1 [4.0%] | |
| >100 | 6 [54.5%] | 4 [36.4%] | 1 [9.1%] | |
| Yes | 47 [63.5%] | 22 [29.7%] | 5 [6.8%] | 0.551 |
| No | 38 [57.6%] | 25 [37.9%] | 3 [45.4%] | |
MSK - Musculoskeletal; TJA - Total Joint Arthroplasty; PJI - Prosthetic Joint Infection; B&J - Bone and Joint